CHPA Pushes Federal Legislation, PSAs To Curb Dextromethorphan Abuse
This article was originally published in The Tan Sheet
Executive Summary
The Consumer Healthcare Products Association is actively working to encourage introduction of companion legislation in the Senate for a bill that would restrict the sale and distribution of bulk forms of dextromethorphan
You may also be interested in...
Bill To Restrict Bulk DXM Sales Reintroduced In House
Legislation reintroduced by Reps. Fred Upton, R-Mich., and Rick Larsen, D-Wash., Feb. 8 would restrict online sales of bulk dextromethorphan to entities registered with FDA, but does not propose methods of preventing abuse of OTC cough medicines
Dextromethorphan Bulk-Sale Limit Clears House, But Stalls In Senate
House leadership made a lame duck priority of legislation to restrict sales and distribution of bulk forms of dextromethorphan (DXM), but HR 5280 did not get the same treatment in the Senate
DXM legislation
The "Dextromethorphan Distribution Act of 2006" (H.R. 5280) now has 13 cosponsors and has been referred to the House Committee on Energy & Commerce, the Consumer Healthcare Products Association states July 26. The bill would allow FDA to limit the distribution of the bulk ingredient to only those people or entities that are registered with the agency and would make it more difficult for teens to abuse the drug. Stephen Pasierb of the Partnership for a Drug-Free America spoke about CHPA's efforts to curb abuse of OTCs during a July 26 hearing held by the House Government Reform Subcommittee on Criminal Justice, Drug Policy & Human Resources. CHPA and the Partnership launched a public service campaign in May to inform consumers about the dangers of abusing DXM and other Rx and OTC drugs (1"The Tan Sheet" May 22, 2006, p. 4)...